A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

NCT02100722 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2026-04-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in similar outcomes to coronary artery bypass graft surgery (CABG).

Conditions

  • Coronary Disease
  • Coronary Stenosis

Interventions

PROCEDURE

FFR guided PCI

PROCEDURE

CABG

Coronary Artery Bypass Graft Surgery (CABG)

DEVICE

Resolute Integrity Stent

Durable polymer zotarolimus-eluting stent

DEVICE

Resolute Onyx Stent

Durable polymer zotarolimus-eluting stent

Sponsors & Collaborators

  • VZW Cardiovascular Research Center Aalst

    collaborator OTHER
  • Catharina Ziekenhuis Eindhoven

    collaborator OTHER
  • Golden Jubilee National Hospital

    collaborator OTHER_GOV
  • University of California, Irvine

    collaborator OTHER
  • Medtronic

    collaborator INDUSTRY
  • Abbott Medical Devices

    collaborator INDUSTRY
  • Genae

    collaborator INDUSTRY
  • King's College Hospital NHS Trust

    collaborator OTHER
  • Houston Methodist DeBakey Heart & Vascular Center

    collaborator OTHER
  • Stanford University

    lead OTHER

Principal Investigators

  • William F Fearon, MD · Stanford University

  • Nico HJ Pijls, MD, PhD · Catharina Hospital Eindhoven, The Netherlands

  • Bernard De Bruyne, MD, PhD · VZW Cardiovascular Research Center Aalst

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-25
Primary Completion
2020-12-01
Completion
2024-12-01

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Czechia
  • Denmark
  • France
  • Hungary
  • Lithuania
  • Netherlands
  • New Zealand
  • Norway
  • Serbia
  • South Korea
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02100722 on ClinicalTrials.gov